PUBLISHER: GlobalData | PRODUCT CODE: 1410836
PUBLISHER: GlobalData | PRODUCT CODE: 1410836
Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Mycobacterium Tuberculosis Tests market for the year 2020 and beyond. The tuberculosis (TB) infection has two modes of existence, latent TB and active TB. For latent TB, the mycobacterium is dormant within the body. The majority of individuals do not exhibit symptoms, but these patients are considered to be at risk for developing an active TB infection. Tuberculosis can be detected by a number of different tests including the tuberculosis skin test (TST), blood tests of interferon gamma release assays (IGRA), nucleic acid amplification tests (NAATs), sputum smear microscopy tests, and culture tests. Additionally, chest x-Rays are also often used to help diagnose TB infection. Multidrug-resistant tuberculosis is an increasingly serious threat to the eradication of global TB. Hard to diagnose due to the inconsistent testing infrastructure and lack of laboratory specialists and clinicians. MDR-TB is defined as the TB bacilli being resistant to at least isoniazid and rifampicin, while XDR-TB is resistant to more medicaments including fluoroquinolone, and to one of the three injectable drugs (amikacin, kanamycin, and capreomycin).
The Mycobacterium Tuberculosis diagnostic tests include IGRA and Mycobacterium Tuberculosis NAAT tests.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Mycobacterium Tuberculosis Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Qiagen NV, Oxford Immunotec Ltd, Danaher Corp, Molbio Diagnostics Pvt Ltd, Hologic Inc, F. Hoffmann-La Roche Ltd, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable